Pharmaceutical Business review

Caraco Pharma Q2 net sales rise

Caraco Pharma has posted a net loss of $1.51m for the second quarter 2010, or $0.04 loss per diluted share, compared to net income of $6.67m, or $0.16 per diluted share, for the comparable period in 2009.

Operating loss was $2.45m, compared to operating income of $10.56m for the comparable period in 2009.

For the six months ended 30 September 2010, Caraco Pharma has posted net sales of $227.82m, compared to $126.45m for the year ago period.

Net loss was $298,048, or $0.01 loss per diluted share for the six months ended 30 September 2010, compared to $2.75m, or $0.07loss per diluted share, for the year ago period.

Operating loss was 867,821, compared to $3.79m for the year ago period.

Detroit-based Caraco Pharma manufactures, develops, markets and distributes generic pharmaceuticals to wholesalers, distributors, drugstore chains and managed care providers.